JP2005536444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005536444A5 JP2005536444A5 JP2003534384A JP2003534384A JP2005536444A5 JP 2005536444 A5 JP2005536444 A5 JP 2005536444A5 JP 2003534384 A JP2003534384 A JP 2003534384A JP 2003534384 A JP2003534384 A JP 2003534384A JP 2005536444 A5 JP2005536444 A5 JP 2005536444A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- nhc
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 94
- 150000001875 compounds Chemical class 0.000 claims 34
- 238000000034 method Methods 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- -1 s- butyl Chemical group 0.000 claims 7
- 239000011612 calcitriol Substances 0.000 claims 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 6
- 239000000018 receptor agonist Substances 0.000 claims 6
- 229940044601 receptor agonist Drugs 0.000 claims 6
- 102000009310 vitamin D receptors Human genes 0.000 claims 6
- 108050000156 vitamin D receptors Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 claims 3
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 235000020964 calcitriol Nutrition 0.000 claims 2
- 229960005084 calcitriol Drugs 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- ADXLZWYVJHRTST-BIWMIDHDSA-N (1r,2r,3s,4r,5s,6s)-2-amino-6-(hydroxymethyl)-7-oxabicyclo[4.1.0]heptane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](N)[C@H]2O[C@]21CO ADXLZWYVJHRTST-BIWMIDHDSA-N 0.000 claims 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 0 C[C@](CCCC(C(C)(C)C)=*OC)C([C@@]1(C)CCC2)=CC[C@]1C2=CC=C(C[C@](C1)O)C[C@]1O Chemical compound C[C@](CCCC(C(C)(C)C)=*OC)C([C@@]1(C)CCC2)=CC[C@]1C2=CC=C(C[C@](C1)O)C[C@]1O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32842801P | 2001-10-12 | 2001-10-12 | |
| PCT/CA2002/001519 WO2003031400A1 (en) | 2001-10-12 | 2002-10-11 | Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005536444A JP2005536444A (ja) | 2005-12-02 |
| JP2005536444A5 true JP2005536444A5 (enExample) | 2006-01-19 |
| JP4436674B2 JP4436674B2 (ja) | 2010-03-24 |
Family
ID=23280940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534384A Expired - Fee Related JP4436674B2 (ja) | 2001-10-12 | 2002-10-11 | １α，２５−ジヒドロキシビタミンＤ３の低カルシウム血症性オキシム類似体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6982258B2 (enExample) |
| EP (1) | EP1436257B1 (enExample) |
| JP (1) | JP4436674B2 (enExample) |
| AT (1) | ATE360000T1 (enExample) |
| CA (1) | CA2463505C (enExample) |
| CY (1) | CY1106638T1 (enExample) |
| DE (1) | DE60219655T2 (enExample) |
| DK (1) | DK1436257T3 (enExample) |
| ES (1) | ES2283593T3 (enExample) |
| PT (1) | PT1436257E (enExample) |
| WO (1) | WO2003031400A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242434B1 (en) | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| EP2070911A2 (en) | 2000-07-18 | 2009-06-17 | Bone Care International, Inc. | Stabilized 1Alpha-Hydroxy vitamin D |
| US20050059641A1 (en) * | 2003-06-17 | 2005-03-17 | Aphios Corporation | Compositions and methods for treating and preventing cancer using analogs of vitamin D |
| US20050192255A1 (en) * | 2003-07-30 | 2005-09-01 | Jin Tian | Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease |
| AU2005244061A1 (en) * | 2004-05-10 | 2005-11-24 | Novacea, Inc. | Prevention of arterial restenosis with active vitamin D compounds |
| US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| WO2006032299A1 (en) * | 2004-09-24 | 2006-03-30 | Susanna Miettinen | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| WO2006074227A2 (en) * | 2005-01-04 | 2006-07-13 | Johns Hopkins University | HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS |
| WO2006113990A2 (en) * | 2005-04-25 | 2006-11-02 | Cytochroma Inc. | LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3 |
| JP5303276B2 (ja) * | 2005-10-12 | 2013-10-02 | プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー | ２５−ヒドロキシビタミンｄ不足および欠乏を治療するための方法および製品 |
| CA2882048C (en) * | 2006-02-03 | 2020-03-24 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| EP2679228B1 (en) | 2006-06-21 | 2018-03-21 | Opko Ireland Global Holdings, Ltd. | Therapy using vitamin D repletion agent and vitamin D hormone replacement agent |
| US9481646B2 (en) * | 2007-04-18 | 2016-11-01 | The Johns Hopkins University | Low calcemic, highly antiproliferative, analogs of calcitriol |
| EP3225243B1 (en) | 2007-04-25 | 2025-09-03 | Opko Renal, LLC | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| WO2009047644A2 (en) * | 2007-04-25 | 2009-04-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| KR101759244B1 (ko) | 2007-04-25 | 2017-07-18 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| US8592401B2 (en) * | 2007-04-25 | 2013-11-26 | Proventiv Therapeutics, Llc | Methods and compounds for vitamin D therapy |
| US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2009120565A2 (en) | 2008-03-25 | 2009-10-01 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| CN106853250A (zh) * | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| EP2393827B1 (en) | 2009-02-05 | 2015-10-07 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| US20100227414A1 (en) * | 2009-03-05 | 2010-09-09 | Trex Enterprises Corp. | Affinity capture mass spectroscopy with a porous silicon biosensor |
| JP5887672B2 (ja) * | 2010-01-13 | 2016-03-16 | シトクロマ インコーポレイテッド | ビタミンｄ関連化合物の１−デオキシ類似体 |
| SI2552484T1 (sl) | 2010-03-29 | 2020-07-31 | Opko Ireland Global Holdings, Ltd. | Postopki in sestavki za znižanje ravni paratiroidnega hormona |
| RU2015137617A (ru) | 2013-03-14 | 2017-04-18 | Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер | Агенты, подавляющие андрогенные рецепторы, и их применение |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| KR20160058774A (ko) | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| CN104557647B (zh) * | 2015-01-13 | 2016-07-06 | 南京理工大学 | 维生素d肟类衍生物、合成方法及其应用 |
| CN104945296B (zh) * | 2015-06-09 | 2016-08-24 | 南京理工大学 | 一类芳香醛腙修饰的维生素d2衍生物、合成及其应用 |
| CA3018019A1 (en) | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
| CN117003679A (zh) * | 2022-04-29 | 2023-11-07 | 南澳大利亚大学 | 新型抑制剂化合物 |
| WO2025094144A1 (en) | 2023-11-02 | 2025-05-08 | Eirgen Pharma Ltd. | Controlling loss of kidney function |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481198A (en) * | 1984-02-13 | 1984-11-06 | Wisconsin Alumni Research Foundation | Vitamin D metabolism inhibitor |
| GB9623569D0 (en) * | 1996-11-13 | 1997-01-08 | Immunodiagnostic Systems Ltd | Vitamin D immumoassay systems |
-
2002
- 2002-10-11 PT PT02767010T patent/PT1436257E/pt unknown
- 2002-10-11 DK DK02767010T patent/DK1436257T3/da active
- 2002-10-11 CA CA2463505A patent/CA2463505C/en not_active Expired - Lifetime
- 2002-10-11 ES ES02767010T patent/ES2283593T3/es not_active Expired - Lifetime
- 2002-10-11 JP JP2003534384A patent/JP4436674B2/ja not_active Expired - Fee Related
- 2002-10-11 WO PCT/CA2002/001519 patent/WO2003031400A1/en not_active Ceased
- 2002-10-11 DE DE60219655T patent/DE60219655T2/de not_active Expired - Lifetime
- 2002-10-11 EP EP02767010A patent/EP1436257B1/en not_active Expired - Lifetime
- 2002-10-11 AT AT02767010T patent/ATE360000T1/de active
- 2002-10-15 US US10/270,158 patent/US6982258B2/en not_active Expired - Lifetime
-
2007
- 2007-06-04 CY CY20071100741T patent/CY1106638T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005536444A5 (enExample) | ||
| CA2463505A1 (en) | Low-calcemic oxime analogs of 1.alpha.,25-dihydroxy vitamin d3 | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| AU2007234717A1 (en) | 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof | |
| JP2005519083A5 (enExample) | ||
| JP2019014758A5 (enExample) | ||
| JP2005534635A5 (enExample) | ||
| EP0909560A3 (en) | Treatment o tumors with compounds having RXR retinoid receptor agoinst activity | |
| CN1694711A (zh) | 扩大维生素剂量范围的方法 | |
| JP2004507465A5 (enExample) | ||
| RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
| CA2488334A1 (en) | 24-sulfoximine vitamin d3 compounds | |
| TW200934782A (en) | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | |
| JP2015522551A5 (enExample) | ||
| RU2013128973A (ru) | Соединения, активные в отношении кальций-чувствительных рецепторов | |
| ZA202207541B (en) | Substituted triazinones as thyroid hormone receptor agonists | |
| JP2005521676A5 (enExample) | ||
| US20240390399A1 (en) | Materials and methods for suppressing and/or treating bone related diseases and symptoms | |
| EP2968346B1 (en) | Methods and compositions for gamma-glutamyl cycle modulation | |
| JP2007515467A5 (enExample) | ||
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| JP2013518812A5 (enExample) | ||
| CA2510228A1 (en) | 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3 | |
| RU95113434A (ru) | Диметилбензофураны и диметилбензопираны, их применение в качестве 5-нт*003-антагонистов, способы их получения, фармацевтическая композиция | |
| TW200522967A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |